BIOGEN INC. Debt Securities, Available-for-sale, Realized Loss
BIOGEN INC. (BIIB) reported Debt Securities, Available-for-sale, Realized Loss of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-06.
Financial Statements › Income Statement › Other Income
us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss · last filed 2026-02-06
- BIOGEN INC. debt securities, available-for-sale, realized loss for the quarter ending 2023-12-31 was $36.80M, a 68.04% increase year-over-year.
- BIOGEN INC. debt securities, available-for-sale, realized loss for the quarter ending 2023-09-30 was -$16.30M.
- BIOGEN INC. debt securities, available-for-sale, realized loss for the quarter ending 2023-06-30 was -$1.40M.
- BIOGEN INC. debt securities, available-for-sale, realized loss for the quarter ending 2023-03-31 was -$700.00K.
- BIOGEN INC. debt securities, available-for-sale, realized loss for fiscal 2025 was $0.00.
- BIOGEN INC. debt securities, available-for-sale, realized loss for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- BIOGEN INC. debt securities, available-for-sale, realized loss for fiscal 2023 was $18.40M, a 46.03% increase from fiscal 2022.
- BIOGEN INC. debt securities, available-for-sale, realized loss for fiscal 2022 was $12.60M, a 215.00% increase from fiscal 2021.
| Period end | Debt Securities, Available-for-sale, Realized Loss 3 month | Debt Securities, Available-for-sale, Realized Loss 3 month as first filed | Debt Securities, Available-for-sale, Realized Loss 6 month | Debt Securities, Available-for-sale, Realized Loss 6 month as first filed | Debt Securities, Available-for-sale, Realized Loss 9 month | Debt Securities, Available-for-sale, Realized Loss 9 month as first filed | Debt Securities, Available-for-sale, Realized Loss 12 month |
|---|---|---|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-02-06 | ||||||
| 2024-12-31 | $0.00 10-K · filed 2026-02-06 | ||||||
| 2023-12-31 | $36.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-06 | $20.50M derived: sum of 2 quarters · filed 2026-02-06 | $19.10M derived: sum of 3 quarters · filed 2026-02-06 | $18.40M 10-K · filed 2026-02-06 | |||
| 2023-09-30 | -$16.30M 10-Q · filed 2024-10-30 | -$17.70M derived: sum of 2 quarters · filed 2024-10-30 | -$18.40M 10-Q · filed 2024-10-30 | $3.50M derived: sum of 4 quarters · filed 2025-02-12 | |||
| 2023-06-30 | -$1.40M 10-Q · filed 2024-08-01 | -$2.10M 10-Q · filed 2024-08-01 | $19.80M derived: sum of 3 quarters · filed 2025-02-12 | $11.90M derived: sum of 4 quarters · filed 2025-02-12 | |||
| 2023-03-31 | -$700.00K 10-Q · filed 2024-04-24 | $21.20M derived: sum of 2 quarters · filed 2025-02-12 | $13.30M derived: sum of 3 quarters · filed 2025-02-12 | $12.50M derived: sum of 4 quarters · filed 2025-02-12 | |||
| 2022-12-31 | $21.90M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-12 | $14.00M derived: sum of 2 quarters · filed 2025-02-12 | $13.20M derived: sum of 3 quarters · filed 2025-02-12 | $12.60M 10-K · filed 2025-02-12 | |||
| 2022-09-30 | -$7.90M 10-Q · filed 2023-11-08 | -$8.70M derived: sum of 2 quarters · filed 2023-11-08 | -$9.30M 10-Q · filed 2023-11-08 | -$3.60M derived: sum of 4 quarters · filed 2024-02-14 | |||
| 2022-06-30 | -$800.00K 10-Q · filed 2023-07-25 | -$1.40M 10-Q · filed 2023-07-25 | $4.30M derived: sum of 3 quarters · filed 2024-02-14 | $3.80M derived: sum of 4 quarters · filed 2024-02-14 | |||
| 2022-03-31 | -$600.00K 10-Q · filed 2023-04-25 | $5.10M derived: sum of 2 quarters · filed 2024-02-14 | $4.60M derived: sum of 3 quarters · filed 2024-02-14 | $4.10M derived: sum of 4 quarters · filed 2024-02-14 | |||
| 2021-12-31 | $5.70M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-14 | $5.20M derived: sum of 2 quarters · filed 2024-02-14 | $4.70M derived: sum of 3 quarters · filed 2024-02-14 | $4.00M 10-K · filed 2024-02-14 | |||
| 2021-09-30 | -$500.00K 10-Q · filed 2022-10-25 | $500.00K 10-Q · filed 2021-10-20 | -$1.00M derived: sum of 2 quarters · filed 2022-10-25 | -$1.70M 10-Q · filed 2022-10-25 | $1.70M 10-Q · filed 2021-10-20 | -$900.00K derived: sum of 4 quarters · filed 2023-02-15 | |
| 2021-06-30 | -$500.00K 10-Q · filed 2022-07-20 | $500.00K 10-Q · filed 2021-07-22 | -$1.20M 10-Q · filed 2022-07-20 | $1.20M 10-Q · filed 2021-07-22 | -$400.00K derived: sum of 3 quarters · filed 2023-02-15 | $500.00K derived: sum of 4 quarters · filed 2023-02-15 | |
| 2021-03-31 | -$700.00K 10-Q · filed 2022-05-03 | $700.00K 10-Q · filed 2021-04-22 | $100.00K derived: sum of 2 quarters · filed 2023-02-15 | $1.00M derived: sum of 3 quarters · filed 2023-02-15 | $6.20M derived: sum of 4 quarters · filed 2023-02-15 | ||
| 2020-12-31 | $800.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-15 | $1.70M derived: sum of 2 quarters · filed 2023-02-15 | $6.90M derived: sum of 3 quarters · filed 2023-02-15 | $26.00M 10-K · filed 2023-02-15 | |||
| 2020-09-30 | $900.00K 10-Q · filed 2021-10-20 | $6.10M derived: sum of 2 quarters · filed 2021-10-20 | $25.20M 10-Q · filed 2021-10-20 | $26.00M derived: sum of 4 quarters · filed 2022-02-03 | |||
| 2020-06-30 | $5.20M 10-Q · filed 2021-07-22 | $24.30M 10-Q · filed 2021-07-22 | $25.10M derived: sum of 3 quarters · filed 2022-02-03 | $25.20M derived: sum of 4 quarters · filed 2022-02-03 | |||
| 2020-03-31 | $19.10M 10-Q · filed 2021-04-22 | $19.90M derived: sum of 2 quarters · filed 2022-02-03 | $20.00M derived: sum of 3 quarters · filed 2022-02-03 | $20.30M derived: sum of 4 quarters · filed 2022-02-03 | |||
| 2019-12-31 | $800.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-03 | $900.00K derived: sum of 2 quarters · filed 2022-02-03 | $1.20M derived: sum of 3 quarters · filed 2022-02-03 | $1.50M 10-K · filed 2022-02-03 | |||
| 2019-09-30 | $100.00K 10-Q · filed 2020-10-21 | $400.00K derived: sum of 2 quarters · filed 2020-10-21 | $700.00K 10-Q · filed 2020-10-21 | $1.60M derived: sum of 4 quarters · filed 2021-02-03 | |||
| 2019-06-30 | $300.00K 10-Q · filed 2020-07-22 | $600.00K 10-Q · filed 2020-07-22 | $1.50M derived: sum of 3 quarters · filed 2021-02-03 | $2.10M derived: sum of 4 quarters · filed 2021-02-03 | |||
| 2019-03-31 | $300.00K 10-Q · filed 2020-04-23 | $1.20M derived: sum of 2 quarters · filed 2021-02-03 | $1.80M derived: sum of 3 quarters · filed 2021-02-03 | $2.60M derived: sum of 4 quarters · filed 2021-02-03 | |||
| 2018-12-31 | $900.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-03 | $1.50M derived: sum of 2 quarters · filed 2021-02-03 | $2.30M derived: sum of 3 quarters · filed 2021-02-03 | $11.70M 10-K · filed 2021-02-03 | |||
| 2018-09-30 | $600.00K 10-Q · filed 2019-10-22 | $1.40M derived: sum of 2 quarters · filed 2019-10-22 | $10.80M 10-Q · filed 2019-10-22 | ||||
| 2018-06-30 | $800.00K 10-Q · filed 2019-07-24 | $10.20M 10-Q · filed 2019-07-24 | |||||
| 2018-03-31 | $9.40M 10-Q · filed 2019-04-24 | ||||||
| 2017-09-30 | $1.20M 10-Q · filed 2018-10-23 | $2.50M derived: sum of 2 quarters · filed 2018-10-23 | $4.40M 10-Q · filed 2018-10-23 | ||||
| 2017-06-30 | $1.30M 10-Q · filed 2018-07-24 | $3.20M 10-Q · filed 2018-07-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |